The prevalence of EGFR mutation in Taiwan was much higher (40.8% to 62.1%) than that in Western countries, indicating that more than half of all lung cancers in Taiwan should be effectively treated with EGFR-TKI [33,34,35]. This evidence concerns the gene EGFR and lung cancer.